Laxxon Medical

Laxxon Medical is thrilled to announce our collaboration with CDMO Adare Pharma Solutions. “Laxxon’s partnership with Adare represents a significant step forward in actualizing our mission to drive disruptive global drug delivery and manufacturing solutions,” said Helmut Kerschbaumer, Laxxon Medical CEO. The partnership permits direct scaling from Laxxon’s laboratory quantities through to clinical trial material volumes at Adare's cGMP facility in Milan, Italy. A second SPID®-Technology production system is planned for installation at Adare's Ohio facility at the end of Q4 2024. Learn more here: https://lnkd.in/eh9fAbBm

Adare CEO Tom Sellig shares insights into the company’s CDMO solutions in this interview from CPHI Milan. Learn how Adare is embracing innovative pharmaceutical technologies like 3D printing, which enhances drug delivery by allowing for customizable formulations and optimized release profiles tailored to patient needs.   Learn more about Adare ➡️ https://lnkd.in/ec7gnxcf #CDMO #Pharma #CPHI

Need help with patent protection or extension for your drug product? Laxxon Medical’s proprietary 3D screen printing manufacturing platform can be leveraged to extend the life of your patent or protect your novel drug product. ·     Optimize or reformulate pharmaceuticals currently on the market ·     Repurpose, reposition, and relaunch generic APIs ·     Integrate new APIs previously incompatible with traditional pill pressing Learn how you can partner with us to strengthen your position in the market: https://lnkd.in/dmQvYurx #PharmaceuticalManufacturing # 3Dprinting #3DPrintingTechnology #MedicalInnovation #AdditiveManufacturing #MedicalTechnology #MedicalTech #Pharmacokinetics #DrugDevelopment #PharmaTech #DrugDelivery

Our mission is clear—to improve the lives of patients everywhere by providing pharmaceuticals that are safer, easier to take, and more effective. By advancing 3D screen printing technology together with Exentis Group AG, we are delivering pharmaceuticals with customized pharmacokinetics, precise dosing, improved solubility, and enhanced bioavailability that can improve patient compliance and outcomes. In addition, our precisely-controlled and scalable manufacturing processes allow for the reduction of adverse side effects and the addition of on-pill QR coding for easier identification and direct access to product and safety information. Learn more about our impactful pharmaceutical manufacturing technology: https://lnkd.in/euzsfviE #PharmaceuticalManufacturing #3Dprinting #3DPrintingTechnology #MedicalInnovation #AdditiveManufacturing #MedicalTechnology #MedicalTech #Pharmacokinetics #DrugDevelopment #PharmaTech #DrugDelivery #InnovateWithUs #LaxxonMedical

We’re making smart drug delivery systems available for every patient. At Laxxon Medical, we utilize our proprietary SPID® (Screen Printed Innovative Drug) Technology to rapidly manufacture innovative, precise smart drug delivery systems at scale. Our unique additive manufacturing platform can be used to tailor pharmacokinetics based on advanced geometric internal structures, variable distribution of APIs, and choice of materials. Global pharmaceutical companies partner with us to develop novel medicines and advanced generics, from R&D to full-scale production, and leverage our unique processes for patent extension on existing drugs. Learn how you can innovate with us:  https://lnkd.in/euzsfviE #PharmaceuticalManufacturing #3Dprinting #3DPrintingTechnology #MedicalInnovation #AdditiveManufacturing #MedicalTechnology #MedicalTech #Pharmacokinetics #DrugDevelopment #PharmaTech #DrugDelivery #InnovateWithUs #LaxxonMedical

After another successful week spent at our manufacturing site in Pessano con Bornago, the countdown to #bioeurope by EBD Group has started! This year I won’t be there running from meeting to meeting, however our partners from Laxxon Medical will be in Stockholm! Don’t miss the chance to schedule a meeting with Klaus Kühne and Achim Schneeberger to learn about Laxxon’s additive manufacturing solutions and rich pipeline: https://lnkd.in/d9BR5jG3 #cdmo #pharmaceuticals

At Laxxon Medical, we are disrupting the pharmaceutical industry with an innovative manufacturing platform. We’ve developed 3D screen printing technology that produces novel, smart drug delivery systems at scale. Our unique capabilities enable us to quickly produce customized medications with: ·     Increased API bioavailability ·     Enhanced solubility ·     Fewer adverse side effects ·     Improved patient compliance Explore how you can leverage this technology to develop more effective therapeutics or extend patents on existing formulations: https://lnkd.in/dmQvYurx #PharmaceuticalManufacturing #3Dprinting #3DPrintingTechnology #MedicalInnovation #AdditiveManufacturing #MedicalTechnology #MedicalTech #Pharmacokinetics #DrugDevelopment #PharmaTech #DrugDelivery #InnovateWithUs

Tune into the live webcast of Laxxon Medical's fireside chat at the UBS Global Health Conference on November 14th, 2024 with CEO Helmut Kerschbaumer. Learn more here: https://lnkd.in/erezp6AH

Laxxon has developed an enteric coated oral tablet and multi-compartment micro-tablets of a GLP-1 agonist combined with a permeation enhancer to now offer adequate bioavailability upon oral intake using our proprietary 3D printing manufacturing process, SPID®. LXM.2 is designed to provide patients with a once-daily oral medication to replace the daily or weekly injections. LXM.2 is developed as a solid tablet as well as in form of micro tablets (≤ 1 mm). In its form of the Multi-Compartment Micro Tablets, it addresses increased patient compliance in special patient groups, such as pediatrics. Laxxon is thrilled to be presenting LXM.2 at Biotechnology Innovation Organization Europe this year – schedule a meeting with us to learn more about our latest 3DSP developments! Learn more here: https://lnkd.in/eC4M-jJW #InnovateWithUs #LaxxonMedical #GLP1 #microtablet

Are you a pharmaceutical company looking to transform your current assets, or acquire new ones? Laxxon Medical is a leading pharma-technology company pioneering a new generation of advanced pharmaceuticals through SPID®-Technology, a 3D screen-printing platform technology. Laxxon's pipeline includes ongoing working-projects with notable pharma players, biotech companies and research universities, in addition to 13 in-house Advanced Patented Generics products. Laxxon's IP is continuously growing and consists of 230+ patents and patent applications with more than 5,000 patent claims. We would love to meet with you at BIO to discuss our platform, our development programs, and the licensing of our assets. Schedule a meeting with us at Biotechnology Innovation Organization Europe here: https://lnkd.in/dSh2WhAN